Despite numerous treatments, the majority of Australians with osteoporosis remain untreated. The newer parenteral treatments, intravenous zoledronic acid and subcutaneous denosumab injections, are administered less frequently (annually or six monthly, respectively) than the oral bisphosphonates, potentially overcoming compliance issues. Two other daily treatments − strontium ranelate and teriparatide − do not have major inhibitory effects on bone resorption (anti-catabolic), and teriparatide stimulates new bone formation (anabolic). with the exception of teriparatide, which is reserved for women and men with the most severe osteoporosis, all of these newer drugs are first-line therapy for osteoporosis in postmenopausal women. However, only bisphosphonates are also currently approved for this indication in men and in patients with corticosteroid-induced osteoporosis.
introduction osteoporosis results from reduced bone strength and predisposes patients to an increased risk of fracture. Bone strength is determined by both bone density and bone quality.
All fractures due to osteoporosis reduce the quality of life and increase mortality. The most common sites of minimal trauma fractures are the hip and pelvis (40.5%) and wrist and forearm (17.1%). Hip fracture is the most catastrophic of osteoporotic fractures resulting in chronic pain, disability and increased mortality in up to 35% of patients within 12 months. 1, 2 Conservative estimates indicate that 692 300 Australians (Table 1) . A summary of their safety and efficacy is shown in Table 2 .
Zoledronic acid
Bisphosphonates are synthetic analogues of pyrophosphate and bind to bone mineral with high affinity. They are taken up by osteoclasts during bone resorption and either inhibit the adenosine triphosphate (etidronate or clodronate) or farnesyl pyrophosphate synthase (aminobisphosphonates) pathways. 3 This inhibits bone resorption through reduced recruitment of osteoclasts and decreased osteoclast activity, with formation of giant dysfunctional osteoclasts. 4 Zoledronic acid is the most potent bisphosphonate and has the longest skeletal half-life. It is administered as an intravenous infusion (5 mg in 100 mL) over at least 15 minutes once 
Efficacy
In a large placebo-controlled clinical trial, zoledronic acid treatment reduced vertebral fractures by 70% (10.9% vs 3.3%, p<0.001), non-vertebral fractures by 25% (10.7% vs 8.0%, p<0.001) and hip fractures by 41% (2.5% vs 1.4%, p=0.002) over three years in postmenopausal women with osteoporosis. 5 All-cause mortality decreased by 28% (13.3% vs 9.6%, p=0.01) and all clinical fractures by 35% (13.9% vs 8.6%, p=0.001) in older men and women who received zoledronic acid 5 mg versus placebo within three months of sustaining a hip fracture. 6 The mechanisms responsible for mortality reduction in patients treated with zoledronic acid remain unclear, but may be related to an effect on reducing cardiovascular events and pneumonia. 7 If treatment was deferred for two weeks after the fracture, the improvements in bone mineral density and reductions in mortality and re-fracture rate were greater. 8 
Adverse effects
Infusion-related acute-phase reactions are common, occurring in about a third of patients after the first infusion, and only 7% and 3% of patients after the second and third infusion, respectively. 5 Symptoms including fever, myalgia, influenza-like symptoms, headache, nausea and arthralgia occur for 1-3 days.
Giving paracetamol shortly after the infusion reduces these In postmenopausal women with osteoporosis, the incidence of serious atrial fibrillation was increased versus placebo (1.3% vs 0.5%, p<0.001). 5 However, as this was not found in the other zoledronic acid trials, the association remains uncertain and a report from the Food and Drug Administration found no association between bisphosphonates and atrial fibrillation. Rare events reported with both oral and intravenous bisphosphonates include severe ocular inflammation, and severe and incapacitating musculoskeletal pain. In this trial, atypical femoral fractures did not occur. 5 In osteoporosis trials of zoledronic acid, there was only one case of osteonecrosis of the jaw reported in each of the treatment and placebo groups. The risk is estimated to be very low (about 1:10 000) and is most strongly associated with high cumulative intravenous bisphosphonate doses in patients with malignancy, rather than in patients with osteoporosis.
Denosumab
Denosumab is a fully human monoclonal antibody to RANKL 
Efficacy
When given as a 60 mg subcutaneous injection every six months, compared with placebo, denosumab increases the bone mineral density at the lumbar spine and hip, with associated relative risk reductions of 68% (7.2% vs 2.3%, 
Adverse effects
Denosumab is well tolerated with adverse effect rates generally similar to placebo. 9, [11] [12] [13] [14] [15] [16] The most common adverse reactions include musculoskeletal pain, hypercholesterolaemia and eczema, and discontinuation should be considered if the latter is severe. 13 osteonecrosis of the jaw has rarely been reported (two cases) and a routine oral examination is recommended before starting treatment. 17 In patients with bone metastases from breast or prostate cancer, osteonecrosis of the jaw may be associated with denosumab treatment, suggesting decreased bone turnover may be an important contributing factor.
Strontium ranelate
Although the mechanism of action of strontium is unclear, this orally administered daily treatment decreases bone resorption, increases bone formation markers and maintains bone microarchitecture. It should be administered two hours after the evening meal for optimal absorption and should not be taken at the same time as calcium supplements.
Efficacy
Strontium increased spinal and hip bone density and reduced vertebral fractures by 41% (32.8% vs 20.9%, p<0.001) and nonvertebral fractures by 16% (12.9% vs 11.2%, p=0.04) in postmenopausal women with osteoporosis over three years in the SoTI trial, 18 and for up to five years in the TRoPoS trial. 19 A post hoc analysis showed it also reduces hip fractures in women aged 74 years and over with a T-score of -3.0 or less. 19 Strontium also reduces vertebral and non-vertebral fractures and improves quality of life in women aged over 80 years 20, 21 and reduces vertebral fractures in postmenopausal women with or without prevalent fractures and osteopenia. 22 www.australianprescriber.com increases in bone mineral density after strontium treatment are related to fracture risk reduction.
Adverse effects
The annual incidence of venous thromboembolism over five years was 0.9% with strontium ranelate versus 0.6% with placebo (relative risk of 1.4). 23 Treatment needs to be initiated by a specialist and treatment duration is limited to 18 months.
Efficacy
Teriparatide therapy increases spine and hip bone mineral density and reduces vertebral and non-vertebral fractures in postmenopausal women. 27 It has similar effects in men but there are no data on non-vertebral fractures. 28, 29 The effect of teriparatide on hip fracture reduction has not been reported for men or women. Decreases in vertebral fractures of 65% (14% vs 5%, p<0.001) and non-vertebral fractures by 53% (6% vs 3%, p=0.02) compared with placebo in postmenopausal women are similar to those seen with zoledronic acid and denosumab. A meta-analysis has shown that severe back pain was reduced by 61% with teriparatide compared to the comparators (placebo, alendronate or hormonal therapy). 30 The risk reduction for back pain was evident after only six months of teriparatide. 
Adverse effects
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New drugs for osteoporosis
The newer drugs for the management of osteoporosis widen the range of treatment options, but are not without risk. The main dental concern is bisphosphonate-related osteonecrosis of the jaw. It took several years before the true relation and incidence of bisphosphonate-related osteonecrosis was established and accepted. Multiple independent studies have shown a relation between osteonecrosis after dental extraction and bisphosphonate use. The incidence is approximately 1/500 to 1/1500. For patients taking intravenous bisphosphonates for cancer who have dental extractions the incidence is much higher at 1/10-15. 1
At present, the incidence of osteonecrosis of the jaw for patients on intravenous zoledronic acid and subcutaneous denosumab for osteoporosis is unknown, but is probably low. 
